With early phase 1 data now out in the wild, metabolic disease outfit Metsera is wasting no time locking down supplies of its ...

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company"), a global pharmaceutical company, and Metsera, Inc. ("Metsera"), a clinical-stage biopharmaceutical company accelerating the ...

The race to supply obesity drugs is so competitive that one early-stage startup is already striking a deal for commercial ...

Amneal Pharmaceuticals (AMRX) and Metsera have entered into a collaboration agreement to enable the efficient development and ...

Metsera, a biotech focused on obesity treatments, came out of stealth only this year, and its lead drug is still in early ...

MolecuLight Inc., the global leader in fluorescence imaging technology for real-time detection of harmful bacteria and ...

Modine , a diversified global leader in thermal management technology and solutions, announced today that Mark Bendza will join the company's Board of Directors effective immediately. Mr. Bendza ...

On the heels of a $3 billion fund from Bain Capital Life Sciences, Arch Venture Partners is proving it can go toe-to-toe with ...

A biotech-focused venture capital firm in Chicago is ready with a new fund as life sciences and biotech continue to find new ...

Obesity startup Metsera is getting a new manufacturing partner and a new CEO. On Tuesday, the well-funded startup announced ...

Chicago-based venture-capital firm Arch Venture Partners has closed a new $3 billion fund to invest in early-stage ...

ARCH Venture Partners today announced the closing of ARCH Venture Fund XIII, a venture capital fund with more than $3 billion ...